BPMUF.US Basilea Pharmaceutica AG

Healthcare Biotechnology USA Stocks
84.00 USD
Close of Nov 13, 2026
59.29 84.00
Market cap
USD 1.04B
P/E
16.6x
P/B
5.26x
ROE
68.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is BPMUF.US undervalued?

Graham number
Price84.00
Graham value42.61
Premium97.1%

BPMUF.US trades 97.1% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Basilea Pharmaceutica AG fundamental analysis

No fundamental analysis for Basilea Pharmaceutica AG yet.

Basilea Pharmaceutica AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Basilea Pharmaceutica AG

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), acute bacterial skin, community-acquired bacterial pneumo…

Full company profile